Keensight Capital completed the acquisition of Axxam from Bayer and Zambon.

Keensight Capital, a private equity firm, completed the acquisition of Axxam, a profitable and innovative Partner Research Organization, from Bayer, a medical company, and Zambon, a modern healthcare company. “Axxam is a true pioneer and leader in its field, one of the few biology-centric drug research partners globally. Many clients have benefited from compounds identified and advanced by Axxam’s specialized research techniques and brilliant scientists. In addition, Axxam’s client-focused model perfectly fits our strategy of investing in highly profitable, fast-growing leaders in attractive and resilient niches of the healthcare and technology industries. It is a real honor for us to be able to partner with Axxam’s founders and management team,” Amit Karna, Keensight Capital Partner.